Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

Forbes files for U.S. patent related to membrane deficiencies

Jan. 20, 1997

IDEC licenses technology to Boehringer Ingelheim

Jan. 17, 1997

Medarex forms European subsidiary and research alliance

Jan. 17, 1997

Lilly and TheraTech drug collaboration

Jan. 16, 1997

ArQule and Signal expand drug discovery agreement

Jan. 16, 1997

NeXstar reveals new oligonucleotide synthesis method

Jan. 13, 1997

Labopharm granted US patent on drug delivery system

Jan. 10, 1997

Access/Strakan license agreement

Jan. 10, 1997

SIBIA Neurosciences/Aurora Biosciences drug discovery technology agreement

Jan. 10, 1997

Genetics Institute/Ontogeny functional genomics agreement

Jan. 10, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.